KR20110130969A - A composition for improving lipid metabolism which includes extract of rubus coreanus as an active constituent by major - Google Patents

A composition for improving lipid metabolism which includes extract of rubus coreanus as an active constituent by major Download PDF

Info

Publication number
KR20110130969A
KR20110130969A KR1020100050557A KR20100050557A KR20110130969A KR 20110130969 A KR20110130969 A KR 20110130969A KR 1020100050557 A KR1020100050557 A KR 1020100050557A KR 20100050557 A KR20100050557 A KR 20100050557A KR 20110130969 A KR20110130969 A KR 20110130969A
Authority
KR
South Korea
Prior art keywords
composition
extract
lipid metabolism
improving lipid
weight
Prior art date
Application number
KR1020100050557A
Other languages
Korean (ko)
Other versions
KR101173172B1 (en
Inventor
양승용
성기승
진재순
김기성
임상동
박민희
Original Assignee
한국식품연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국식품연구원 filed Critical 한국식품연구원
Priority to KR1020100050557A priority Critical patent/KR101173172B1/en
Publication of KR20110130969A publication Critical patent/KR20110130969A/en
Application granted granted Critical
Publication of KR101173172B1 publication Critical patent/KR101173172B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/234—Cnidium (snowparsley)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Botany (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

PURPOSE: A composition containing Rubi Fructus for improving lipid metabolism is provided to reduce plasma cholesterol and neutral lipid. CONSTITUTION: A complex composition for improving lipid metabolism contains extract of 60-70wt% of Rubi Fructus, 10-15 wt% of Rosamultifloravar. Rosa multiflora var. platyphylla, 10-15 wt% of Torilis japonica, and 10-15 wt% of Zea mays Linne as an active ingredient. A method for preparing the composition comprises: a step of pulverizing Rubi Fructus, Rosamultifloravar. Rosa multiflora var. platyphylla, Torilis japonica, and Zea mays Linne; a step of isolating the pulverized herbs using solvent; and a step of compressing and freeze-drying. The solvent is purified water, methanol, or ethanol.

Description

복분자를 주성분으로 하는 한약재 추출물을 유효성분으로 포함하는 지질대사 개선용 조성물{A composition for improving lipid metabolism which includes extract of rubus coreanus as an active constituent by major}A composition for improving lipid metabolism which includes extract of rubus coreanus as an active constituent by major}

본 발명은 혈장 콜레스테롤 및 중성지방을 조절 할 수 있는 한약재 조성물로서 복분자를 주성분으로 하고 영실자, 사상자 및 옥촉서예의 추출물을 유효성분으로 하는 지질대사 개선용 조성물에 관한 것이다.
The present invention relates to a composition for improving lipid metabolism, which is a medicinal herb composition that can control plasma cholesterol and triglyceride as a main ingredient and extracts of Youngsilja, casualties and Okmok calligraphy as active ingredients.

본 발명은 혈장 콜레스테롤 및 중성지방을 조절 할 수 있는 복분자, 영실자, 사상자, 옥촉서예 열수 추출물의 복합 조성물에 관한 것이다. 비만증은 신체의 에너지 요구량보다 더 많은 에너지를 섭취하여 체지방이 축적되어 체중이 증가하는 것으로서, 각종 호르몬과 기타 조절작용에 의해 지방세포 내 과도한 지방이 축적되며 지방세포에 지방의 축적은 지방세포의 수와 크기를 증가시킨다. 혈장 콜레스테롤 및 중성지방을 조절하여 지질대사를 개선하고 자 하는 시도가 많이 있었으나, 노력한 만큼 효과를 보지 못하고 있는 실정이다.The present invention relates to a composite composition of Bokbunja, Youngsilja, Casualties, Okmok calligraphy hot water extract that can control plasma cholesterol and triglyceride. Obesity is an increase in body fat by ingesting more energy than the body's energy requirements, which leads to the accumulation of excess fat in fat cells by various hormones and other regulatory actions. And increase the size. There have been many attempts to improve lipid metabolism by regulating plasma cholesterol and triglycerides, but the situation is not as effective.

복분자(覆盆子; Rubus Coreanum Miquel, Rubi Fructus)는 장미과의 복분자딸기의 채 익지 않은 열매로 만든 약재로서 신(腎)기능을 북돋아 유정(遺精), 몽정(夢精), 유뇨(遺尿) 등에 사용하며, 시력약화에 쓰고 몸을 가볍게 하고 머리를 검게 하며 살결을 부드럽고 아름답게 한다. 약리작용으로 항염작용, 항산화작용, 항 헬리코박터 파이로리 작용이 보고되고 있으며, 비만세포 활성화 억제효과, 체중 조절 효과, 혈중지질성분 변화에 효과, 항산화효과 혈압저해효과, 향균효과 등이 보고되었다. 한방에서는 신장기능, 불임증, 음위증, 유정몽설, 강장제로 쓰였으며 혈액과 눈을 맑게 해주며, 간을 보호하는 효능을 가지고 있다고 알려져 있으며, 탄수화물 분해 효소 저해작용이 다소 있고, 영양성분으로는 무기질의 인과 철 칼륨이 많이 함유하고 있고 특히 유기산과 비타민C가 많이 포함되어 있으며, 페놀 화합물로 aempferol, quercerin 등이 보고되었다. 복분자 나무의 잎, 줄기에는 tannic acid, flavonoids 화합물 등이 함유되어 있으며 복분자 열매에는 gallic acid, 2.3-HHDD-D0glucopyyranose sanguin 등이 함유되어 있으며, 종래에 복분자 추출물을 유효성분으로 포함하는 비만방지 또는 치료용 조성물, 항비만용 아밀라제 저해제 및 용도에 대한 특허나, 혈중지질 및 혈당조절효과에 관한 논문들도 보고되고 있다.Bokbunja (覆盆子; Rubus Coreanum Miquel, Rubi Fructus) is a medicinal herb made from unripe fruits of the rose family Bokbunja strawberry. It is used for oil wells, dream tablets, and urination. It is used to weaken eyesight, lighten the body, darken the hair and make the skin soft and beautiful. Anti-inflammatory, antioxidant and anti-Helicobacter pylori actions have been reported as pharmacological actions, and the effects of inhibiting mast cell activation, weight control, changes in blood lipid components, antioxidant effects, blood pressure inhibitory effects, and antibacterial effects have been reported. In oriental medicine, it is used as kidney function, infertility, vulgaris, well-being dream, tonic, and it is known to clear the blood and eyes, and to protect the liver, and to inhibit carbohydrate degrading enzymes. It contains a lot of phosphorus and potassium, especially organic acid and vitamin C. Aempferol and quercerin have been reported as phenolic compounds. The leaves and stems of the bokbunja tree contain tannic acid and flavonoids compounds, and the bokbunja fruit contains gallic acid, 2.3-HHDD-D0glucopyyranose sanguin, and it is conventionally used for preventing or treating obesity containing bokbunja extract as an active ingredient. Patents on compositions, anti-obesity amylase inhibitors and their use, and papers on blood lipid and glycemic control effects have also been reported.

영실자는 덩굴찔레(Rosamultifloravar. platyphylla)의 열매를 영실(營實)이라 하며, 지방세포 분화 및 체중증가를 억제하는 기능이 있음이 알려져 있으며, 풍열과 습열을 없애는 효능이 있어 이뇨, 신장염, 각기, 월경통 등을 치료하는 데 쓰였다. 민간에서는 꽃과 열매를 복진통, 관절염, 자상 등을 치료하는 약재로, 뿌리를 기침, 해소, 치통 등을 치료하는 약재로 각각 사용한다. 영실로부터 multiflorin A, multiflorin B, kaemferol 3-α-L-rhamnoside, multinoside A와 acetate, quercitrin, isoquercitrin, quercetin 3-O-xyloside, hyperin등의 flavonoid와 scoparone, salicylic acid, sterol 등이 보고되어있으며, 향균력을 나타낸다고 알려져 있다. 덩굴찔레의 어린 새가지는 껍질을 벗겨 그대로 먹거나, 생채로 무쳐 먹기도 하며 부드러운 순을 덖어 차로 만들면 향기가 그대로 살아난다. 향이 좋아 찔레꽃을 증류해 화장수로 이용하기도 한다. 덩굴장미의 대목으로 이용하며, 뿌리는 단단하고 불에 잘 타지 않아 담배 파이프나 고급가구의 재료로도 쓰인다. Youngsil is the fruit of Rosamultifloravar.platyphylla called Youngsil, and it is known that it has the function of suppressing fat cell differentiation and weight gain, and it is effective in eliminating wind and moist fever, diuresis, nephritis, each, It was used to treat dysmenorrhea, etc. In folk medicine, flowers and fruits are used to treat abdominal pain, arthritis, and cuts, and roots are used to treat coughs, relieve pain, and toothache. Multiflorin A, multiflorin B, kaemferol 3-α-L-rhamnoside, multinoside A and flavonoids such as acetate, quercitrin, isoquercitrin, quercetin 3-O-xyloside, hyperin, scoparone, salicylic acid, and sterol have been reported from Youngsil. It is known to show antibacterial activity. Peeled young twigs of vine brisk can be eaten as peeled or eaten as raw vegetables. If you make tea with soft sprouts, the fragrance will survive. The fragrance is also good for distilling brier flowers. It is used as the root of the vine rose, and its roots are hard and do not burn well, so it is also used for tobacco pipes and high-quality furniture.

사상자(蛇床子; Torilis japonica)는 산형과(Umbelliferae)에 속하는 사상(Torilis japonica)의 과실로써 식품공전 상에 식품 부원료로 분류되어 있으며 한의서에 습창 완선, 음중 종통, 옴 등의 피부질환에 유효하다고 기록되어 있다. 어린순은 나물로 하고 열매는 수렴, 소염약, 살충, 발기부전에 사용하며, 최근들어 비만치료용 조성물에 사용되어지고 있다. 사상자(Torilis fructus)의 약리작용에 관한 연구로는 진통소염작용, 진경작용, anti-invasive efficacy 등이 보고되어 있다. 또한 주름개선 실험인 collagen 합성 촉진 효과, collagenase 저해 효과에서 뛰어난 효과를 나타낸다고 보고된 바 있다. 사상자의 성분으로는 정유성분인 stigmasterol, β-sitosterol, cholesterol과 6α-diol, torilin등 9종의 guaian-type sesquiterpenoids가 알려져 있으며, essential oil과 sesquiterpenoid 화합물 등이 보고되어 있다. Torilis japonica is a fruit of Torilis japonica, belonging to the Umbelliferae family, and is classified as a food ingredient in the Korean food industry. It is recorded. Young sprout is herb and fruit is used for astringent, anti-inflammatory medicine, insecticide, erectile dysfunction, and recently it has been used in composition for treating obesity. Studies on the pharmacological effects of Tolis fructus have reported analgesic, anti-inflammatory, anti-invasive efficacy. In addition, it has been reported to show an excellent effect in the collagen synthesis promoting effect, collagenase inhibitory effect in the wrinkle improvement experiment. Nine kinds of guaian-type sesquiterpenoids, such as stigmasterol, β-sitosterol, cholesterol, 6α-diol, and torilin, which are essential oil components, are known, and essential oils and sesquiterpenoid compounds have been reported.

옥촉서예란 우리나라에서는 벼과의 옥수수(Zea mays Linne)의 신선한 꽃대(화주:花柱)와 암술머리(주두:柱頭)를 말한다. 옥촉서예란 열대아메리카원산인 옥수수의 수염을 채집하여 건조한 것으로 특이한 냄새가 조금 나고 맛은 달고 담담하며 성질은 어느 한쪽으로 치우치지 않고 평(甘淡平)하다. 생김새는 가는 실이나 머리카락 모양으로 서로 엉키어 엉성한 덩어리로 되어 있고, 엷은 녹색에서 황녹색 또는 황갈색을 띤다. 질은 부드럽고 매우 가벼우며 광택이 있다. 이명으로는 옥미수(玉米鬚), 옥맥수(玉麥鬚), 옥고량(玉高梁), 포곡수(包穀鬚), 옥촉서(玉蜀黍), 옥미발(玉米髮), 옥발(玉髮) 등이 있다. 옥촉서예(옥수수 수염)는 고유의 신장 개선 기능 및 식이섬유의 배변활동 촉진 기능 등을 통해 변비 및 비만 등의 질병을 예방 할 수 있다고 알려져 있다.Okmok calligraphy refers to fresh flower beds (flower pots) and pistil heads of rice plants (Zea mays Linne) in Korea. Okmok calligraphy is a collection of the beards of corn, native to tropical America, which has a peculiar smell, tastes sweet, and has a mild, unbiased nature. It looks like a thin thread or hair, entangled with one another, and has a light green color to yellowish green or yellowish brown color. The quality is soft and very light and glossy. The tinnitus is jade rice, jade rice, jade goyang, ox goyang, bonggok, octave, jade, valbal, etc. There is this. Okmok calligraphy (corn whiskers) is known to prevent diseases such as constipation and obesity through the intrinsic kidney improvement function and the function of promoting the bowel activity of dietary fiber.

예로부터 민간에서는 고혈압, 강혈당, 토혈, 지혈, 비출혈, 평간, 설열, 각기, 축농증, 이담작용, 이뇨작용, 황달성 간염, 담낭염, 담낭결석 등에 효능이 있다고 보고되어 왔다. 옥수수 수염의 효능으로는 이뇨작용, 당뇨억제효과, COX-2 저해효과, Nitric oxide synthase 유도효과, 간보호 효과 등이 보고되고 있다. 옥수수 수염 유래의 플라보노이드로는 maysin, apimaysin, methoxymaysin이 있으며 이중 maysin은 옥수수 수염에 가장 많이 함유되어 있는 대표적인 기능성 물질로 corn earworm의 생육 억제활성, 종양 세포주에 대한 세포독성 효과 및 라디컬 소거활성 등이 보고되어 있다. 옥수수 수염에는 cyanidin 3-glucoside, cyanidin 3-(6''-malonylglucoside), cyanidin 3-(3'',6''-dimalonylglucoside), peonidin 3-glucoside, peonidin 3-(6''-malonylglucoside) 및 peonidin 3-(dimalonylglucoside)과 같은 다양한 안토시아닌이 존재한다고 한다.It has been reported in the private sector that it is effective in hypertension, hyperglycemia, hemostasis, hemostasis, nasal bleeding, flatulence, fever, each, sinusitis, biliary tract, diuretic, jaundice hepatitis, cholecystitis, and gallbladder stones. Corn whiskers have been reported to have diuretic, diabetic, COX-2 inhibitory effects, nitric oxide synthase induction, and hepatoprotective effects. Flavonoids derived from corn whiskers may include maysin, apimaysin, and methoxymaysin. Among these, maysin is the most functional substance contained in corn whiskers. Its growth inhibitory activity, cytotoxic effect on tumor cell lines, and radical scavenging activity of corn earworms Reported. Corn whiskers include cyanidin 3-glucoside, cyanidin 3- (6 ''-malonylglucoside), cyanidin 3- (3 '', 6 ''-dimalonylglucoside), peonidin 3-glucoside, peonidin 3- (6 ''-malonylglucoside), and Various anthocyanins such as peonidin 3- (dimalonylglucoside) are said to exist.

본 발명과 관련되는 한약재를 이용한 비만예방 및 치료에 관련된 종래기술은 한국특허공개 10-2009-0113554(토별층 추출물 또는 이의 분획물을 유효성분으로 함유하는 비만 또는 동맥경화 예방 및 치료용 조성물)에는 체중, 체지방, 지방세포 크기 증가를 억제하고, 혈중 콜레스테롤 및 중성지방을 감소시키며 지방산화 및 에너지 소비에 관련된 유전자의 발현을 감소시켜 지방산을 분해시키는 유전자의 발현을 감소시킨다. 한국특허공개 10-2009-0108974(복합 한약재 추출물을 포함하는 심혈관계 질환 예방 또는 치료용 조성물)에는 와송, 지우초, 금은화, 귀전우, 마가목, 백지, 마지현 및 우피를 열수 또는 유기용매로 추출한 복합 한약재 추출물은 심혈관계질환, 고콜레스테롤 혈중 예방 및 치료제로 사용된다. 한국특허등록 10-0813187(비만 예방 및 억제능을 갖는 한약재 추출 조성물)은 송엽, 상엽, 자작엽, 향나무, 목과, 금은화의 추출물로 이루어진 비만 예방용 조성물이다. 한국특허공개 10-2007-0111624(한약재 추출물을 유효성분으로 함유하는 관상동맥성 심장 질환비만 또는 동맥경화증 개선용 건강보조식품)에는 흰양삼, 감초, 구기자, 뽕나무잎, 갈근, 하고초, 오갈피, 오미자, 황금, 산약, 황정, 작약 및 생지로 구성된 한약재 추출물의 조성물로서 혈장 및 콜레스테롤 및 중성지방의 농도를 감소시켜 지질대사 개선용 의약품 또는 건강보조식품을 제공한다. 한국특허공개 10-2008-0050794(복합생약 추출물을 함유하는 비만 예방 및 치료용 조성물)는 향부자, 활석, 택란, 당귀,천궁, 백작약, 방풍, 연교, 박하, 마황, 대황, 망초, 석고, 계지, 길경, 황금, 백궁, 치자, 형개, 생강, 감초등의 복합 생약추출물을 복강내 지방 중량 감소 및 낮은 독성으로 비만 예방 및 치료가 가능하다. 한국특허등록 10-0733984(한약재와 곤약을 이용한 비만 또는 고지혈증의 치료 및 예방용 약제학적 조성물)에는 하수오, 택사, 오미자, 결명자, 차조기, 산수유, 산사자, 강황, 휘첨, 반하, 익지, 도인 및 방기로 이루어진 추출물로 체중증가 억제, 식욕감소, 고지혈증 및 지질대사 개선에 유용하다. 한국특허등록 10-0504124(비만 억제용 조성물)에는 길경, 이의인, 숙지황, 차전자피, 천궁 및 잎새버섯을 주성분으로 하고, 식품첨가물을 함유하여 비만증 및 성인병 예방용 조성물을 제공한다. 한국특허공개10- 2005-0013370(한약재를 이용한 비만 치료 조성물)에는 이의인, 택사, 하수오, 산사 및 차전자를 필수 성분으로 하여 그밖에 곡류 중에서 선택된 어느 하나가 포함된 조성물은 체내 흡수율이 높고 비만 치료에 효과가 있다. 그러나 이들 종래기술은 본 발명과는 기술적 구성이 다른 것이다.Prior art related to the prevention and treatment of obesity using herbal medicines related to the present invention is disclosed in Korean Patent Publication No. 10-2009-0113554 (composition for preventing and treating obesity or arteriosclerosis containing an extract or fractions thereof as an active ingredient) In addition, it inhibits the increase in body fat and fat cell size, reduces blood cholesterol and triglycerides, and decreases the expression of genes involved in fatty acidization and energy consumption, thereby reducing the expression of genes that degrade fatty acids. Korean Patent Laid-Open Publication No. 10-2009-0108974 (composition for preventing or treating cardiovascular diseases including a complex herbal extract) includes the extract of Wasong, Jichocho, Geumgumhwa, Haeunwoo, Rowan, White Paper, Marji and Bovine with hot water or organic solvent. Complex herbal extract is used as a preventive and therapeutic agent for cardiovascular disease and high cholesterol blood. Korea Patent Registration 10-0813187 (Herbal extract composition having the ability to prevent and inhibit obesity) is a composition for preventing obesity consisting of extracts of pine needles, upper leaves, birch leaves, juniper, neck and gold and silver. Korean Patent Publication No. 10-2007-0111624 (health supplement for improving obesity or atherosclerosis, which contains herbal extracts as an active ingredient) includes white ginseng, licorice, goji berry, mulberry leaf, brown root, vinegar, ogalpi, and schizandra It is a composition of Chinese herbal medicine extracts consisting of golden, mountain, yellow, peony, and dough to reduce the concentration of plasma and cholesterol and triglycerides to provide a drug or dietary supplement for improving lipid metabolism. Korean Patent Publication No. 10-2008-0050794 (composition for preventing and treating obesity containing complex herbal extracts) is for hyangbuja, talc, talc, donkey, cheongung, earl, windproof, duct, peppermint, ephedra, rhubarb, forget-me-not, gypsum, gyeji Complex herbal extracts, such as Gil-Gyeong, Golden, White Arch, Gardenia, Penguin, Ginger, Licorice, can be used to prevent and treat obesity by reducing abdominal fat weight and low toxicity. Korea Patent Registration 10-0733984 (pharmaceutical composition for the treatment and prevention of obesity or hyperlipidemia using herbal medicine and konjac) includes sewage, taxa, Schisandra chinensis, deficiency, perilla, cornus, hawthorn, turmeric, lottery, half, ripening, fermentation Extract consisting of useful for inhibiting weight gain, decreased appetite, hyperlipidemia and lipid metabolism. Korean Patent Registration 10-0504124 (an obesity inhibiting composition) is the main ingredient of Gilkyung, Yiinin, Sukjihwang, chajeonpi, cheongung and leaf mushrooms, and provides a composition for preventing obesity and adult diseases by containing food additives. Korean Patent Laid-Open Publication No. 10-2005-0013370 (an anti-obesity composition using herbal medicine) includes an object of opposition, taxa, sewage, sansa and cha-jeon as essential ingredients, and any other composition selected from cereals has a high absorption rate in the body and treatment of obesity. Is effective. However, these prior arts have a technical configuration different from the present invention.

비만증은 신체의 에너지 요구량보다 더 많은 에너지를 섭취하여 체지방이 축적되어 체중이 증가하는 것으로서, 각종 호르몬과 기타 조절작용에 의해 지방세포 내 과도한 지방이 축적되며 지방세포에 지방의 축적은 지방세포의 수와 크기를 증가시킨다. 간문맥으로 다량의 유리지방산이 들어가게 되고 간에서 VLDL 및 LDL이 증가되어 중성지방의 합성이 많아져서 높은 중성지방 혈증을 초래하고, 증가된 인슐린은 환원효소(Hydroxymethyl glutaryl CoA reductase)활성화를 항진시켜 콜레스테롤 합성을 촉진시킨다. Obesity is an increase in body fat by ingesting more energy than the body's energy requirements, which leads to the accumulation of excess fat in fat cells by various hormones and other regulatory actions. And increase the size. A large amount of free fatty acid enters the portal vein, and VLDL and LDL are increased in the liver, resulting in high triglyceride synthesis due to increased synthesis of triglycerides.Increased insulin promotes the activation of reductase (Hydroxymethyl glutaryl CoA reductase) To promote.

콜레스테롤은 비만으로 인해 고콜레스테롤 혹은 중성지방이 증가한 상태에서 혈관의 벽에 지방 침전물이 쌓이게 되고 고지혈증, 동맥경화, 협심증, 심근경색, 뇌경색 및 관상동맥증을 일으킬 수 있어 일반적으로 비만의 지표로 이용된다. 따라서 콜레스테롤은 비만과 직접적인 연관을 갖는 다는 것을 알 수 있다. 비만은 식생활의 서구화로 인해 비만인구가 크게 증가하여 국민건강을 위협하는 요인이 되고 있다. Cholesterol is generally used as an indicator of obesity because obesity causes fatty deposits to build up in the walls of blood vessels in the presence of high cholesterol or triglycerides, and can cause hyperlipidemia, arteriosclerosis, angina pectoris, myocardial infarction, cerebral infarction and coronary artery disease. . Therefore, it can be seen that cholesterol is directly related to obesity. Obesity is a threat to national health due to the large increase in obesity due to the westernization of diet.

현재 전 세계 비만인구는 11억명 이상이며, 미국질병통제센터(CDC)는 미국인구의 1/3을 비만(BMI 30이상)인구로 분류하고 있으며, 아동 비만인구 6-11살 연령에서 과체중과 비만율은 28％이고 과체중은 아동의 60％ 이상이 비만아동이다. 1970년대 비율 4％에 비해 무려 7배 늘어난 수치이며 2010년 미국 아동 50％가 과체중이 될 전망이어서 사회비용문제 및 아동의 체력저하문제 등을 야기한다. 우리나라에서는 7년 사이에 약 31kcal정도의 에너지 섭취량이 늘고 활동량이 감소하여 소아청소년 비만은 6.8％(98년)에서 12.0％(05년)으로 7년 사이 2배가 증가하였고(소아, 청소년 신체발육 표준치 제정사업), 청소년 비만율은 8.7％(98년)에서 16％(05년)으로 2배가 증가하였으며, 성인비만은 98년부터 05년까지 매년 0.75％씩 증가하는 추세로 비만인구가 크게 증가하여 전체인구 의 30％를 넘어섰다.(국민건강영양조사 제2기(01년), 제3기(05년)) 최근 국민건강영양조사에 따르면 비만유병률(체질량지수, BMI kg/m2 25이상인 분율)은 전체 19세 이상의 성인의 31.0％, 성인남자의 25.6％, 여자 35.6％으로 시간이 지남에 따라 감소하지 않으며, 증가하거나 유사한 추세를 보이고 있다.(2008 국민건강통계) 이는 미국(NHANES, 만 20세 이상 체질량지수 30kg/m2)의 비만유병률(32.2％)과 비슷한 수준으로, 체지방률은 평균 남 20.7％, 여자 30.3％이며, 연령이 높을수록 증가하고 있다. Currently, there are more than 1.1 billion obese people worldwide, and the Centers for Disease Control (CDC) classifies one third of the American population as obese (over 30 BMI), and is overweight and obese at ages 6-11. The rate is 28% and overweight children are obese children. It is a 7 times increase from the 4% rate in the 1970s, and 50% of US children are expected to become overweight in 2010, causing social costs and children's stamina. In Korea, energy consumption increased by about 31 kcal and activity decreased during 7 years. Child obesity increased from 6.8% (98 years) to 12.0% (05 years) between 7 years. Enactment project), youth obesity rate has doubled from 8.7% (98) to 16% (05), and adult obesity has increased by 0.75% every year from 1998 to 2005. Over 30% of the total population (National Health and Nutrition Survey, 2nd (01) and 3rd (05)) According to the recent National Health and Nutrition Survey, the prevalence of obesity (body mass index, BMI kg / m 2 or more) Fraction) is 31.0% of adults over 19 years old, 25.6% of adult males and 35.6% of females, and does not decrease over time and shows a similar or increasing trend (2008 National Health Statistics). only the prevalence of obesity (32.2%) of 20 years old BMI 30kg / m 2) A similar level, body fat percentage is the average male 20.7%, female 30.3%, and increasing higher age.

이러한 비만은 각종 생활습관병으로 이어져 당뇨, 고혈압, 고지혈증, 뇌질환 등의 환자가 급증하고 있는 실정이며 대장암, 직장암, 전립선암, 유방암, 난소암 등 각종 병의 발생빈도가 높아지고 이들 질병은 평균수명의 증가와 더불어 지속적으로 증가할 것이라는 가설이 일반적 견해이며, 이러한 지질대사 개선 및 비만의 발생원인, 치료 및 예방법, 처방법 등에 관한 보고들이 제시되고 있다.(Eur, J (lin, Nutr, 5(48) 305-325, 1995) 특히, 지질대사 개선이나 비만이나 체중을 감소시키기 위해서 열량이 적고 공복감을 없애주는 생약재 등이 비만개선 및 체중감소에 효과가 있는 것으로 보고되어(Keim and Kies, 1979, Relser, 1987) 우리나라를 비롯한 동양권에서 천연자원 자연추출물의 생리활성에 대한 연구가 활발히 진행되고 있으며, 오랜 세월동안 안전성과 효능이 검증된 여러 식품소재의 이용에 대한 관심이 높아지고 있다. This obesity has led to various lifestyle-related diseases, such as diabetes, hypertension, hyperlipidemia, brain disease, etc. is increasing rapidly, and the incidence of various diseases such as colorectal cancer, rectal cancer, prostate cancer, breast cancer, ovarian cancer increases and these diseases have an average life expectancy The hypothesis that it will continue to increase with the increase in the number of people is a general opinion, and reports on the causes of the improvement of lipid metabolism and the occurrence of obesity, treatment and prevention methods, and prescription methods are suggested. (Eur, J (lin, Nutr, 5 (48) 305-325, 1995) In particular, low calorie and fasting herbal medicines have been reported to be effective in improving obesity and weight loss in order to improve lipid metabolism, reduce obesity and weight (Keim and Kies, 1979, Relser). , 1987) The research on the physiological activity of natural extracts of natural resources is actively conducted in Korea and other Asian countries. There is a growing interest in the use of various food ingredients.

현재 비만개선을 위한 건강식품으로 생약제, 식이섬유 등을 포함하는 제품들이 개발되고 있으나, 가격이 비싸고 이 제품 섭취시 식사량을 줄여 여러 필수 영양소들의 부족이 우려되며, 당뇨, 고혈압, 고지혈증 등의 치료를 위한 의약품들이 개발되고 있으나, 저혈당증, 알레르기, 다뇨증 등의 많은 부작용이 나타난다.
Currently, products containing herbal medicines and dietary fiber are being developed as a health food for improving obesity, but the price is expensive and there is a concern about the lack of various essential nutrients by reducing the amount of meal when ingesting this product. Drugs are being developed, but many side effects such as hypoglycemia, allergies, and urinary tract appear.

본 발명은 한약재 추출물로 구성된 복합 조성물로서 혈장 콜레스테롤 및 중성지방을 조절하므로써 지질대사를 개선시켜 체중을 감소시킨다. 본 발명의 한약재는 복분자를 주성분으로 하고 영실자, 사상자 및 옥촉서예 추출물의 복합 조성물이 동물 실험을 통하여 지질대사 개선 및 향상 효과가 있다는 것을 확인하는 데 있다.
The present invention is a complex composition consisting of the herbal medicine extract to improve the lipid metabolism by controlling plasma cholesterol and triglycerides to reduce the weight. Herbal medicine of the present invention is to confirm that the composite composition of Bokbunja as the main ingredient and the Youngsilja, casualties and Okmok calligraphy extracts have the effect of improving and improving lipid metabolism through animal experiments.

본 발명의 복분자, 영실자, 사상자 및 옥촉서예의 열수추출물의 복합 조성물을 실험동물에 투여 시 뚜렷하게 지질대사 개선 및 향상 효과가 있다.
When the composite composition of the hot water extract of Bokbunja, Youngsilja, Casualties and Okmok calligraphy of the present invention is administered to a test animal, the lipid metabolism is improved and improved.

본 발명은 지질대사 개선용 복합 조성물을 나타낸다.The present invention represents a composite composition for improving lipid metabolism.

본 발명은 복분자, 영실자, 사상자 및 옥촉서예 추출물을 유효성분으로 함유하는 것을 특징으로 하는 지질대사 개선용 복합 조성물을 나타낸다.The present invention represents a composite composition for improving lipid metabolism, characterized in that it contains Bokbunja, Youngsilja, Casualties and Okmok calligraphy extract as an active ingredient.

본 발명은 전체 중량에 대하여 복분자 추출물은 60∼70중량％, 영실자의 추출물은 10∼15 중량％, 사상자의 추출물은 10∼15 중량％ 및 옥촉서예의 추출물은 10∼15 중량％가 함유되는 지질대사 개선용 복합 조성물을 나타낸다.The present invention is a lipid metabolism containing 60-70% by weight of Bokbunja extract, 10-15% by weight of Youngsilja extract, 10-15% by weight of extract of casualty and 10-15% by weight of extract of Okmok calligraphy. The composite composition for improvement is shown.

본 발명에서 복분자를 주성분으로 사용한 이유는 복분자는 술, 건강기능식품, 건강보조식품 등에서 동물실험 및 임상실험을 통하여 비교적 안전하며, 항산화 및 항비만 효과가 뛰어난 것으로 나타나 있고, 국내에서 조달하기가 쉬운 장점이 있기 때문에 선택하게 되었다.
The reason for using bokbunja as the main ingredient in the present invention is that bokbunja is relatively safe through animal experiments and clinical experiments in alcohol, health functional foods, health supplements, etc., and has excellent antioxidant and anti-obesity effects, and is easy to procure in Korea. Because of its advantages, it was chosen.

본 발명은 지질대사 개선용 복합 조성물의 제조방법을 나타낸다.The present invention shows a method for producing a composite composition for improving lipid metabolism.

본 발명은 복분자, 영실자, 사상자 및 옥촉서예를 분말로 만드는 단계와; 상기의 각각의 분말화된 한약재를 용매로 추출하는 단계와; 상기의 추출물을 여과하고, 여과액을 감압농축하여 동결건조하는 단계를 포함하는 지질대사 개선용 복합 조성물의 제조방법을 나타낸다.The present invention comprises the steps of powdering Bokbunja, Youngsilja, Casualties and Okmok calligraphy; Extracting each of the powdered herbal medicines with a solvent; The extract of the present invention is filtered, and the filtrate is concentrated under reduced pressure to lyophilize.

상기에서 용매는 정제수를 사용할 수 있다.In the above, the solvent may be purified water.

상기에서 한약재로 복분자, 영실자, 사상자, 옥촉서예를 시중(경동시장)에서 상등급 제품을 구입하여 믹서를 이용하여 분말로 만든 후, 각각의 한약재 1kg에 대하여 정제수 10∼20ℓ, 바람직하게는 정제수 10ℓ를 넣고 열수 추출한다. 100℃∼120℃에서 2∼6시간, 바람직하게는 4시간 동안 추출한 다음 추출물을 여과하고, 이 여과액을 감압농축기에서 농축하여 -25℃∼-30℃에서 2∼4일 바람직하게는 3일 가량 동결건조하여 각각의 복분자 추출물 분말, 영실자 추출물 분말, 사상자 추출물 분말, 옥촉서예의 추출물 분말을 얻었다. Purchasing Bokbunja, Yeongsilja, Casualties, Okmok calligraphy as a herbal medicine in the market (Gyeongdong Market), and using a mixer to make powder, and then for each 1kg of herbal medicine, purified water 10 ~ 20ℓ, preferably purified water 10ℓ Put in and extract hot water. Extraction for 2 to 6 hours, preferably 4 hours at 100 ℃ to 120 ℃ and then the extract is filtered, the filtrate is concentrated in a vacuum condenser 2 to 4 days at -25 ℃ to -30 ℃ preferably 3 days After freeze-drying, each of Bokbunja extract powder, Youngsilja extract powder, Casualty extract powder, and Okmok calligraphy extract powder were obtained.

상기에서 용매는 탄소수가 1 내지 4개인 알코올 용매를 사용할 수 있으며, 바람직하게는 에탄올 또는 메탄올을 사용할 수 있다.The solvent may be an alcohol solvent having 1 to 4 carbon atoms, preferably ethanol or methanol.

상기에서 한약재로 복분자, 영실자, 사상자, 옥촉서예를 시중(경동시장)에서 상등급 제품을 구입하여 믹서를 이용하여 분말로 만든 후, 각각의 한약재 100g에 대하여 70％ 에탄올 0.6∼0.8ℓ, 바람직하게는 에탄올 0.7ℓ를 가하고 70∼85℃ 수욕조상에서 4∼6시간, 바람직하게는 85℃ 수욕조상에서 5시간 동안 추출하였다. 회전증발농축기에 넣고 감압농축한 후, 암갈색상의 추출물을 -25℃∼-30℃에서 3∼5시간 동안 동결건조하여 분말상태의 각각의 한약재를 얻었다. Buy Bokbunja, Yeongsilja, Casualties, Okmok calligraphy as a herbal medicine in the commercial market (Gyeongdong Market), and make powder by using a mixer, and then, for each 100g of herbal medicine, 0.6% to 0.8L of 70% ethanol, preferably 0.7 L of ethanol was added and extracted for 4-6 hours in a 70-85 ° C. water bath, preferably 5 hours in an 85 ° C. water bath. The mixture was put in a rotary evaporator and concentrated under reduced pressure, and the extract of the dark brown phase was lyophilized at -25 ° C to -30 ° C for 3 to 5 hours to obtain respective herbal medicines in powder form.

상기에서 정제수를 이용하여 추출한 추출물로부터 얻은 한약재 또는 에탄올을 이용하여 추출한 추출물로부터 얻은 한약재를 혼합하여 지질대사 개선용 복합 조성물을 얻을 수 있으며, 이때 각각의 한약재 분말의 혼합비는 지질대사 개선용 복합 조성물 전체 중량에 대하여 복분자 추출물은 60∼70중량％, 영실자의 추출물은 10∼15 중량％, 사상자의 추출물은 10∼15 중량％ 및 옥촉서예의 추출물은 10∼15 중량％가 함유되는 지질대사 개선용 복합 조성물을 나타낸다.
By mixing the herbal medicine obtained from the extract extracted with purified water or the herbal medicine obtained from the extract extracted using ethanol can obtain a composite composition for improving lipid metabolism, wherein the mixing ratio of each herbal medicine powder is the total composite composition for improving lipid metabolism Complex composition for improving lipid metabolism containing 60 to 70% by weight of bokbunja extract, 10 to 15% by weight of extract of Youngsilja, 10 to 15% by weight of extract of casualty and 10 to 15% by weight of extract of Okmok calligraphy Indicates.

본 발명은 상기에서 언급한 지질대사 개선용 복합 조성물 또는 상기에서 언급한 방법에 의해 제조한 지질대사 개선용 복합 조성물에 약제학적으로 허용된 부형제를 포함하는 지질대사 개선용 복합 조성물을 포함한다.
The present invention includes a composite composition for improving lipid metabolism or a composite composition for improving lipid metabolism comprising a pharmaceutically acceptable excipient in the composite composition for improving lipid metabolism prepared by the above-mentioned method.

본 발명은 상기에서 언급한 지질대사 개선용 복합 조성물 또는 상기에서 언급한 방법에 의해 제조한 지질대사 개선용 복합 조성물에 식품학적으로 허용된 부형제를 포함하는 지질대사 개선용 복합 조성물을 포함한다.
The present invention includes a composite composition for improving lipid metabolism, or a composite composition for improving lipid metabolism comprising a food-acceptable excipient in the composite composition for improving lipid metabolism prepared by the above-mentioned method.

본 발명의 지질대사 개선용 조성물에 대해 다양한 조건으로 실시한바, 본 발명의 목적을 달성하기 위해서는 상기에서 언급한 조건에 의해 지질대사 개선용 조성물을 제공하는 것이 바람직하다.
The lipid metabolism improving composition of the present invention was carried out under various conditions, in order to achieve the object of the present invention, it is preferable to provide a composition for improving lipid metabolism under the above-mentioned conditions.

이하 본 발명의 내용을 실시예 및 시험예를 통하여 구체적으로 설명한다. 그러나, 이들은 본 발명을 보다 상세하게 설명하기 위한 것으로 본 발명의 권리범위가 이들에 의해 한정되는 것은 아니다.
Hereinafter, the present invention will be described in detail with reference to Examples and Test Examples. However, these are for the purpose of illustrating the present invention in more detail, and the scope of the present invention is not limited thereto.

<실시예 1-1> 추출물의 제조Example 1-1 Preparation of Extract

한약재로 복분자, 영실자, 사상자, 옥촉서예를 시중(경동시장)에서 상등급 제품을 구입하여 믹서를 이용하여 분말로 만든 후, 각각의 한약재 분말 1kg에 대하여 정제수 10ℓ를 넣고 열수 추출한다. 100℃에서 4시간 가량 추출 다음 추출물을 여과하고, 여과액을 감압농축기에서 농축하여 -30℃에서 3일 동안 동결건조하여 복분자 201.6g, 영실자 305.8g, 사상자 94.0g, 옥촉서예 85.4g의 추출물 분말을 얻었다.
Buy Bokbunja, Yeongsilja, Casualties, Okmok calligraphy as a medicinal herb in commercial market (Gyeongdong Market), make powder using a mixer, and extract 10 liters of purified water for 1kg of each medicinal herb powder. The extract was filtered for 4 hours at 100 ° C., and then the extract was filtered, and the filtrate was concentrated in a reduced pressure condenser and lyophilized at -30 ° C. for 3 days. A powder was obtained.

<실시예 1-2> 추출물의 제조Example 1-2 Preparation of Extract

한약재로 복분자, 영실자, 사상자, 옥촉서예를 시중(경동시장)에서 상등급 제품을 구입하여 믹서를 이용하여 분말로 만든 후, 각각의 한약재 분말 100g을 원형플라스크에 넣고 70％ 에탄올 0.7ℓ를 가하고 85℃ 수욕조상에서 5시간 동안 추출하였다. 회전증발농축기에 넣고 감압농축한 후, 암갈색상의 추출물을 -30℃에서 4시간 동안 동결건조하여 분말상태의 각각의 한약재 추출물을 얻었다.
Buy Chinese medicine, Bokbunja, Yeongsilja, Casualties, Okmok calligraphy in commercial market (Gyeongdong Market), make powder using a mixer, add 100g of each herbal medicine powder to a circular flask, add 0.7ℓ of 70% ethanol, and add 85 Extraction was performed for 5 hours on a water bath. After putting in a rotary evaporator and concentrated under reduced pressure, the extract of the dark brown phase was lyophilized at -30 ° C. for 4 hours to obtain respective herbal extracts in powder form.

<실시예 2>;<Example 2>;

상기 실시예 1-1에서 제조한 복분자, 영실자, 사상자, 옥촉서예의 감압농축한 추출물 분말은 하기 표 1의 배합비로 배합하여 각각의 배합물을 얻었다.The extract powder concentrated under reduced pressure of Bokbunja, Youngsilja, Casualties, and Okmok calligraphy prepared in Example 1-1 was blended in the blending ratio of Table 1 below to obtain respective blends.

한약재 추출물의 배합비(단위:중량％)Blending ratio of herbal extracts (unit: weight%) 구 분division 배합1Formulation 1 배합2Formulation 2 배합3Formulation 3 배합4Formulation 4 배합5Formulation 5 복분자Bokbunja 2525 4040 49.949.9 57.157.1 62.562.5 영실자Young Silja 2525 2020 16.716.7 14.314.3 12.512.5 사상자Casualties 2525 2020 16.716.7 14.314.3 12.512.5 옥촉서예Ok calligraphy 2525 2020 16.716.7 14.314.3 12.512.5

상기의 배합 1-5 중에서 정성적인 식이급여를 통해 중량기준으로 배합 5(복분자: 영실자: 사상자: 옥촉서예가 5:1:1:1의 중량비로 혼합된 배합물)의 비율에서 우수한 결과를 나타내어 다음의 실시예에서는 배합5를 기준하여 한약재를 혼합하여 사용하였다.
The above formula 1-5 shows excellent results in the ratio of the compound 5 (the compound mixed in the weight ratio of 5: 1: 1: 1 Bokbunja: Youngsilja: casualty: Okmokseoje) on a weight basis through qualitative dietary benefits. In the Example was used to mix the herbal medicine based on the formulation 5.

<실험예>: 지질대사 개선 실험Experimental Example: Lipid Metabolism Improvement Experiment

본 발명에서 복분자, 영실자, 사상사, 옥촉서예는 감압농축한 분말을 혼합하여 동물실험에 사용하였다.In the present invention, Bokbunja, Youngsilja, Sasangsa, Okmok calligraphy was used in animal experiments by mixing the concentrated powder under reduced pressure.

가) 실험동물 및 설계 A) Experimental animal and design

한약재 추출물의 지질대사 저해 효과를 알아보기 위하여 생후 6주령된 Sprague-Dawley계 rat 수컷 50마리를 나라바이오텍에서 분양받아 1주간 안정화 시킨 후 평균체중이 211.5±5.60이 되도록 5군(n=10)으로 나누어 총 6주간 사육하였다. 사육기간 중 물과 사료를 자유급식 하였으며 식이는 일반사료(AIN 93G, 삼양실험동물)와 일반사료, 정제돈지, 콜레스테롤(Wako inc. Japan)의 비율을 92 :　7 : 1의 비율로 배합한 고지방 사료를 시험사료로 이용하였고, 시료는 체중의 0.7％(v/w)로 경구투여 하였다. 대조군으로서 일반사료 급여군의 물 투여군(NDC), 고지방사료 급여군의 물 투여군(HDC)으로 나누었으며, 실험군은 모두 고지방사료를 급여하였고, 복분자, 영실자, 사상자, 옥촉서예 한약재 열수추출물 분말을 5:1:1:1의 비율로 혼합하여 물에 용해시킨 혼합액을 체중 1kg당 10mg(HD-HM 10), 100mg(HD-HM 100), 500mg(HD-HM 500)의 농도로 투여하였다. 체중 및 열량섭취량은 주 1회 측정되었고, 혈액은 안구에서 주 1회 채취되었고, 6주간 시료를 경구투여 한 후 간, 신장, 비장, 고환, 신장지방, 고환지방을 적출하여 무게를 측정하였다.
To investigate the lipid metabolism inhibitory effect, 50 male 6-week-old Sprague-Dawley rats were fed from Nara Biotech, stabilized for 1 week, and the mean weight was 211.5 ± 5.60 to 5 groups (n = 10). The animals were raised for six weeks. During the breeding period, water and feed were freely fed, and the diet consisted of a ratio of 92: 7: 1 of general feed (AIN 93G, Samyang experimental animals), general feed, refined pork, and cholesterol (Wako inc. Japan). Feed was used as a test feed, and the sample was orally administered at 0.7% (v / w) of body weight. The control group was divided into water feeding group (NDC) of the general feed feeding group and water feeding group (HDC) of the high fat feeding group, and all experimental groups were fed high fat feed, and bokbunja, Yeongsilja, casualty, and Chinese herbal medicine hot water extract powder The mixed solution dissolved in water by mixing at a ratio of 5: 1: 1: 1 was administered at concentrations of 10 mg (HD-HM 10), 100 mg (HD-HM 100), and 500 mg (HD-HM 500) per kg of body weight. Body weight and calorie intake were measured once a week, blood was collected once a week from the eye, and after 6 weeks of oral administration, the liver, kidney, spleen, testes, kidney fat and testicular fat were extracted and weighed.

나) 화학분석B) chemical analysis

혈액은 안구에서 채혈하여 1시간 동안 10℃에서 정치시킨 후 원심분리(3,000rpm에서 15분)하여 상징액인 혈장을 얻었고 이는 Total cholesterol, HDL cholesterol, LDL cholesterol, Triglyceride 측정에 사용되었다. total cholesterol은 Enzymatic-colorimetry법으로 Cholesterol reagent(Bayer, USA)를 사용, HDL cholesterol은 Enzymatic-colorimetry법으로 Direct HDL-Cholesterol(Bayer, USA)사용, LDL cholesterol은 Elimination enzymatic assay로 LDL-Cholesterol(Bayer, USA)을 사용, Triglyceride는 Lipase, GK, GPD, colorimetry법으로 Triglycerides reagents(Bayer, USA)를 사용하였으며, ADVIA 1650((Bayer, USA)의 기기를 사용하여 분석하였다.
Blood was collected from the eye and allowed to stand for 1 hour at 10 ° C., followed by centrifugation (15 minutes at 3,000 rpm) to obtain supernatant plasma, which was used to measure total cholesterol, HDL cholesterol, LDL cholesterol, and triglyceride. Total cholesterol is obtained by using Cholesterol reagent (Bayer, USA) by Enzymatic-colorimetry method, HDL cholesterol is used by Direct HDL-Cholesterol (Bayer, USA) by Enzymatic-colorimetry method, and LDL cholesterol by Elimination enzymatic assay by LDL-Cholesterol (Bayer, USA) USA), Triglyceride was used as Lipase, GK, GPD, colorimetry method, Triglycerides reagents (Bayer, USA), and analyzed using the ADVIA 1650 ((Bayer, USA) instrument.

다)실험결과C) Experimental results

①체중변화량, 식이섭취량 및 식이효율: ① Weight change, dietary intake and dietary efficiency:

S.D rat의 체중증가량, 식이섭취량, 식이효율은 표 2와 같다. 체중증가량은 일반사료군보다 고지방사료군에서 높게 나타났으며, 고지방사료군에서는 한약재 추출물을 투여하지 않은 군에 비해 한약재 추출물 농도를 달리하여 투여한 군(100, 500mg/kg)에서 감소하였으나, 유의적 차이는 보이지 않았다. 또한, 고지방사료군에서 한약재 추출물 농도를 달리하여 투여하지 않은 군에 비해 투여한 군(10, 100, 500mg/kg)은 대체적으로 더 낮은 식이 섭취량 및 식이효율을 나타내었으나, 유의적 차이는 보이지 않았다. Weight gain, dietary intake, and dietary efficiency of S.D rats are shown in Table 2. The weight gain was higher in the high fat feed group than in the normal feed group, and the high fat feed group was decreased in the group administered with different herbal extract concentrations (100, 500mg / kg) compared to the group not receiving the herbal extract, but No difference was seen. In addition, in the high fat diet group, the group (10, 100, 500mg / kg) showed a lower dietary intake and dietary efficiency than the group not administered with different herbal extract concentrations, but there was no significant difference. .

한약재 추출물 복합 투여군의 체중증가량, 식이섭취량 및 식이효율Weight Gain, Dietary Intake, and Dietary Efficiency of the Herb-Containing Complex Administration Group Group
(0.7％(v/w))Group
(0.7% (v / w)) Body weight gains
(g/day)Body weight gains
(g / day) Feed intake(g/day)Feed intake (g / day) Feeding Efficiency(％)Feeding Efficiency (%) NDCNDC 4.83±0.43NS 4.83 ± 0.43 NS 26.1±1.26NS 26.1 ± 1.26 NS 18.5±1.32NS 18.5 ± 1.32 NS HDCHDC 4.95±0.38NS 4.95 ± 0.38 NS 23.1±0.93NS 23.1 ± 0.93 NS 21.4±1.17NS 21.4 ± 1.17 NS HD-HM 10HD-HM 10 4.95±0.52NS 4.95 ± 0.52 NS 22.7±1.51NS 22.7 ± 1.51 NS 21.8±1.83NS 21.8 ± 1.83 NS HD-HM 100HD-HM 100 4.85±0.52NS 4.85 ± 0.52 NS 22.8±1.26NS 22.8 ± 1.26 NS 21.3±1.78NS 21.3 ± 1.78 NS HD-HM 500HD-HM 500 4.56±0.38NS 4.56 ± 0.38 NS 21.9±1.10NS 21.9 ± 1.10 NS 20.8±1.34NS 20.8 ± 1.34 NS

* Samples orally administered below the dosage 7ml/kg for 6weeks* Samples orally administered below the dosage 7ml / kg for 6weeks

* Mixture ratio of herb medicine extracts = Rubus coreanus(5) : Rosa multiflora(1) : Torilis japonica(1) : Zea mays Linne(1)* Mixture ratio of herb medicine extracts = Rubus coreanus (5) Rosa multiflora (1) : Torilis japonica (1) Zea mays Linne (1)

* NDC : Normal diet - control group (orall administration of water)* NDC: Normal diet-control group (orall administration of water)

* HDC : High fat diet - control group (orall administratio of water)HDC: High fat diet-control group (orall administratio of water)

* HD-HM 10 : High fat diet - herb medicine mixture (oral administration, 10mg/kg) * HD-HM 10: High fat diet-herb medicine mixture (oral administration, 10mg / kg)

* HD-HM 100 : High fat diet - herb medicine mixture (oral administration, 100mg/kg) * HD-HM 100: High fat diet-herb medicine mixture (oral administration, 100mg / kg)

* HD-HM 500 : High fat diet - herb medicine mixture (oral administration, 500mg/kg) * HD-HM 500: High fat diet-herb medicine mixture (oral administration, 500mg / kg)

* Values ore mean±S.E from ten rats done in triplicate* Values ore mean ± S.E from ten rats done in triplicate

* Not significantly different among groups by Duncan's multiple range test at p<0.05* Not significantly different among groups by Duncan's multiple range test at p <0.05

* Means with differen superscript within the same column are significantly different at p<0.05 by Duncan's multiple range test
* Means with differen superscript within the same column are significantly different at p <0.05 by Duncan's multiple range test

②지질개선 실험 결과:　② Geological improvement test results:

S.D rat의 총콜레스테롤 함량, LDL 콜레스테롤 함량, HDL 콜레스테롤 함량, 중성지방 함량은 표 3과 같다. 총콜레스테롤 함량, LDL 콜레스테롤 함량, 중성지방 함량은 고지방식이 섭취군이 일반식이 섭취군에 비해 높은 함량을 나타내었으나 총콜레스테롤, LDL 콜레스테롤에서는 고지방식이 대조군에 비해 한약재 추출물 농도를 달리하여 투여한 모든 군(10, 100, 500mg/kg)에서 유의적으로 감소하였으며 특히, 총콜레스테롤 함량의 경우 HD-HM 500군에서 가장 큰 유의차를 보였다. 중성지방의 함량은 고지방식이 섭취군들 중 대조군에 비하여 한약재 추출물을 투여한 모든 군에서 농도의존적으로 감소하였고, 특히 HD-HM 500군에서 유의적 차이를 보였다. 또한 동맥경화 발생지표인 동맥경화지수의 경우 총콜레스테롤과 같은 양상을 나타내었는데, 고지방식이섭취 대조군이 가장 높은 ??량을, 일반식이섭취 대조군이 가장 낮은 함량을 나타내었고, 고지방식이섭취 대조군에 비해 한약재 추출물 복합 투여군은 농도의존적으로 그 수치가 감소하였으며 유의적차이를 나타내었다. 그러나 HDL 콜레스테롤은 24.6∼25.5mg/dl로 군들 간의 유의적 차이가 없었다. 콜레스테롤 및 중성 지질의 농도가 줄어 든 것은 콜레스테롤의 농도가 줄어든 것은 항산화물질 등이 간의 콜레스테롤 합성을 낮추거나 변으로 담즙산이나 스테롤의 배설증가에 기인하는 것으로 생각된다.Total cholesterol content, LDL cholesterol content, HDL cholesterol content and triglyceride content of S.D rats are shown in Table 3. The total cholesterol, LDL cholesterol and triglyceride contents were higher in the high-fat diet group than in the normal diet group, but the total cholesterol and LDL-cholesterol extracts were administered with different herbal extract concentrations than the control group. In the group (10, 100, 500mg / kg) was significantly decreased, especially the total cholesterol content was the largest difference in the HD-HM 500 group. The triglyceride content was decreased in all the groups fed the medicinal herb extract in the high fat diet group compared to the control group, especially in HD-HM 500 group. In addition, the arteriosclerosis index, which is an index of atherosclerosis, showed the same pattern as total cholesterol, and the high-fat diet control group had the highest ??, the normal diet-control group had the lowest content, and the high-fat diet control group Compared with the medicinal herb extract group, the concentration decreased and showed a significant difference. However, HDL cholesterol was 24.6-25.5 mg / dl, which was not significantly different among the groups. Decreased concentrations of cholesterol and neutral lipids are thought to be due to decreased cholesterol levels in the liver, such as antioxidants, or increased excretion of bile acids and sterols as feces.

한약재 추출물 복합 투여한 쥐의 혈장 콜레스테롤, 중성지방 함량 및 동맥경화지수Plasma Cholesterol, Triglyceride Contents and Atherosclerosis Index in Rats Treated with Herbal Extracts 항목Item Total cholesterolTotal cholesterol HDL CholesterolHDL Cholesterol AIAI LDL CholesterolLDL Cholesterol TriglycerideTriglyceride NDCNDC 64.1
±5.732a 64.1
± 5.732 a 25.5
±2.759NS 25.5
± 2.759 NS 1.558
±0.113a 1.558
± 0.113 a 7.0
±0.816a 7.0
± 0.816 a 63.8
±8.812a 63.8
± 8.812 a HDCHDC 79.6
±10.126c 79.6
± 10.126 c 24.8
±2.150NS 24.8
± 2.150 NS 2.144
±0.394c 2.144
± 0.394 c 11.7
±2.563c 11.7
± 2.563 c 90.8
±14.907b 90.8
± 14.907 b HD-HM 10HD-HM 10 73.7
±7.746bc 73.7
± 7.746 bc 24.6
±2.413NS 24.6
± 2.413 NS 1.972
±0.316bc 1.972
± 0.316 bc 9.9
±1.069b 9.9
± 1.069 b 85.6
±24.957b 85.6
± 24.957 b HD-HM 100HD-HM 100 72.9
±8.268bc 72.9
± 8.268 bc 24.6
±2.413NS 24.6
± 2.413 NS 1.987
±0.246bc 1.987
± 0.246 bc 9.1
±1.215b 9.1
± 1.215 b 83.9
±17.133b 83.9
± 17.133 b HD-HM 500HD-HM 500 66.9
±4.512ab 66.9
± 4.512 ab 25.1
±3.414NS 25.1
± 3.414 NS 1.706
±0.257ab 1.706
± 0.257 ab 8.3
±0.951b 8.3
± 0.951 b 79.8
±14.240ab 79.8
± 14.240 ab

* Samples orally administered below the dosage 7ml/kg for 6weeks* Samples orally administered below the dosage 7ml / kg for 6weeks

* Mixture ratio of herb medicine extracts = Rubus coreanus(5) : Rosa multiflora(1) : Torilis japonica(1) : Zea mays Linne(1)* Mixture ratio of herb medicine extracts = Rubus coreanus (5) Rosa multiflora (1) : Torilis japonica (1) Zea mays Linne (1)

* NDC : Normal diet - control group (orall administration of water)* NDC: Normal diet-control group (orall administration of water)

* HDC : High fat diet - control group (orall administratio of water)HDC: High fat diet-control group (orall administratio of water)

* HD-HM 10 : High fat diet - herb medicine mixture (oral administration, 10mg/kg) * HD-HM 10: High fat diet-herb medicine mixture (oral administration, 10mg / kg)

* HD-HM 100 : High fat diet - herb medicine mixture (oral administration, 100mg/kg) * HD-HM 100: High fat diet-herb medicine mixture (oral administration, 100mg / kg)

* HD-HM 500 : High fat diet - herb medicine mixture (oral administration, 500mg/kg) * HD-HM 500: High fat diet-herb medicine mixture (oral administration, 500mg / kg)

* Values ore mean±S.E from ten rats done in triplicate* Values ore mean ± S.E from ten rats done in triplicate

* Not significantly different among groups by Duncan's multiple range test at p<0.05* Not significantly different among groups by Duncan's multiple range test at p <0.05

* Means with differen superscript within the same column are significantly different at p<0.05 by Duncan's multiple range test* Means with differen superscript within the same column are significantly different at p <0.05 by Duncan's multiple range test

* A.I(Atherogenic index)=(Total cholesterol - HDL cholesterol)/HDL cholesterol
* AI (Atherogenic index) = (Total cholesterol-HDL cholesterol) / HDL cholesterol

③장기무게:　③ Long-term weight:

S.D rat의 장기무게의 함량은 표 4와 같다. 신장, 비장 및 고환의 무게는 대체로 추출물의 투여 농도가 높아질수록 낮아지는 경향을 보이나, 유의적 차이가 없는 것으로 나타나, 한약재 추출물 복합 투여가 실험동물의 식이 섭취에 영향을 미치지 않는 것으로 보인다. 간의 무게는 일반식이 섭취군보다 고지방식이 섭취군이 훨씬 높은 값을 나타내며 고지방식이 섭취군에서는 한약재 추출물에 대해 유의적으로 농도의존적인 감소 경향을 보이고 있다. 특히 HD-HM 500군에서 가장 큰 유의적 차이를 보이는 것으로 나타났다. 고환지방의 함량은 고지방식이 섭취 대조군과 HD-HM 10군이 일반식이 섭취 대조군에 비해 높게 나타났으나 HD-HM 100과 HD-HM 500군에서는 일반식이 섭취 대조군보다 오히려 낮은 수치를 보였으며, 특히 HD-HM 500군은 가장 큰 차이를 보였다. 신장지방은 고지방식이 섭취 대조군>HD-HM 10>일반식이 섭취 대조군>HD-HM 100>HD-HM 500의 순으로 나타나 추출물 투여에 따른 농도의존적인 감소경향을 나타내었으나, 유의적 차이는 나타나지 않았다. 이 결과는 섭취한 과량의 콜레스테롤과 중성지방이 체외로 정상적으로 배출되지 못하고 간장 내에 축적되어 간 무게와 체중이 증가 된 것으로 보이는 반면, 간 무게가 유의적으로 줄어든 것은 추출물의 경구투여가 간 조직의 지방축적을 억제하여 감소한 것으로 생각된다.The organ weights of S.D rats are shown in Table 4. The weight of kidney, spleen and testicles tended to decrease as the concentration of the extract was increased, but there was no significant difference, and the combination of herbal medicine extract did not appear to affect the dietary intake of the experimental animals. The liver weight was significantly higher in the high-fat diet group than in the normal diet group, and the high-fat diet group showed a significant concentration-dependent decrease in the herbal medicine extract. In particular, the HD-HM 500 group showed the largest significant difference. The content of testicular fat was higher in the high-fat diet control group and the HD-HM 10 group than the general diet intake group, but the HD-HM 100 and HD-HM 500 group showed lower values than the normal diet intake group. In particular, the HD-HM 500 group showed the biggest difference. Kidney fat was found in the order of high-fat dietary control group> HD-HM 10> general dietary control group> HD-HM 100> HD-HM 500, showing a tendency of concentration-dependent decrease according to the administration of extract. Did. These results indicate that excess cholesterol and triglycerides ingested are not normally excreted in vitro and accumulate in the liver, resulting in an increase in liver weight and body weight. It is thought that it reduced by suppressing accumulation.

한약재 추출물을 복합 투여한 쥐의 장기무게 비교(단위 : g)Comparison of organ weights of rats treated with herbal extracts (unit: g) 항목Item LiverLiver Fat of
kidneyFat of
kidney Fat of
testiclesFat of
testicles KidneyKidney SpleenSpleen testiclestesticles NDCNDC 14.59±1.07a 14.59 ± 1.07 a 2.34±0.58NS 2.34 ± 0.58 NS 2.08±0.37ab 2.08 ± 0.37 ab 1.43±0.07NS 1.43 ± 0.07 NS 0.89±0.18NS 0.89 ± 0.18 NS 1.53±0.10NS 1.53 ± 0.10 NS HDCHDC 18.07±1.67c 18.07 ± 1.67 c 2.53±0.59NS 2.53 ± 0.59 NS 2.28±0.51b 2.28 ± 0.51 b 1.43±0.06NS 1.43 ± 0.06 NS 0.89±0.11NS 0.89 ± 0.11 NS 1.56±0.29NS 1.56 ± 0.29 NS HD-HM 10HD-HM 10 17.67±1.55bc 17.67 ± 1.55 bc 2.44±0.66NS 2.44 ± 0.66 NS 2.15±0.42ab 2.15 ± 0.42 ab 1.40±0.11NS 1.40 ± 0.11 NS 0.88±0.10NS 0.88 ± 0.10 NS 1.43±0.06NS 1.43 ± 0.06 NS HD-HM 100HD-HM 100 17.05±1.53bc 17.05 ± 1.53 bc 2.24±0.45NS 2.24 ± 0.45 NS 1.97±0.20ab 1.97 ± 0.20 ab 1.39±0.16NS 1.39 ± 0.16 NS 0.87±0.12NS 0.87 ± 0.12 NS 1.45±0.14NS 1.45 ± 0.14 NS HD-HM 500HD-HM 500 16.59±1.04b 16.59 ± 1.04 b 2.14±0.45NS 2.14 ± 0.45 NS 1.90
±0.19a 1.90
± 0.19 a 1.35±0.08NS 1.35 ± 0.08 NS 0.87±0.24NS 0.87 ± 0.24 NS 1.45±0.08NS 1.45 ± 0.08 NS

* Samples orally administered below the dosage 7ml/kg for 6weeks* Samples orally administered below the dosage 7ml / kg for 6weeks

* Mixture ratio of herb medicine extracts = Rubus coreanus(5) : Rosa multiflora(1) : Torilis japonica(1) : Zea mays Linne(1)* Mixture ratio of herb medicine extracts = Rubus coreanus (5) Rosa multiflora (1) : Torilis japonica (1) Zea mays Linne (1)

* NDC : Normal diet - control group (orall administration of water)* NDC: Normal diet-control group (orall administration of water)

* HDC : High fat diet - control group (orall administratio of water)HDC: High fat diet-control group (orall administratio of water)

* HD-HM 10 : High fat diet - herb medicine mixture (oral administration, 10mg/kg) * HD-HM 10: High fat diet-herb medicine mixture (oral administration, 10mg / kg)

* HD-HM 100 : High fat diet - herb medicine mixture (oral administration, 100mg/kg) * HD-HM 100: High fat diet-herb medicine mixture (oral administration, 100mg / kg)

* HD-HM 500 : High fat diet - herb medicine mixture (oral administration, 500mg/kg) * HD-HM 500: High fat diet-herb medicine mixture (oral administration, 500mg / kg)

* Values ore mean±S.E from ten rats done in triplicate* Values ore mean ± S.E from ten rats done in triplicate

* Not significantly different among groups by Duncan's multiple range test at p<0.05* Not significantly different among groups by Duncan's multiple range test at p <0.05

* Means with differen superscript within the same column are significantly different at p<0.05 by Duncan's multiple range test
* Means with differen superscript within the same column are significantly different at p <0.05 by Duncan's multiple range test

<적용예 1> 식품학적 부형제를 포함하는 지질대사 개선용 조성물<Application Example 1> Composition for improving lipid metabolism comprising a food excipient

상기 표 1의 배합5로 배합된 조성물과 식품학적으로 허용되는 부형제로서 하기 표 5에 기재된 각각의 성분을 혼합하여 불고기소스 형태의 식품학적 부형제를 포함하는 지질대사 개선용 조성물을 제조하였다.
A composition for improving lipid metabolism comprising a food excipient in the form of bulgogi sauce was mixed by mixing each of the ingredients listed in Table 5 as a composition and a food acceptable excipient in Formulation 5 of Table 1.

<적용예 2> 식품학적 부형제를 포함하는 지질대사 개선용 조성물<Application Example 2> Composition for improving lipid metabolism containing a food excipient

상기 표 1의 배합5로 배합된 조성물과 식품학적으로 허용되는 부형제로서 하기 표 5에 기재된 각각의 성분을 혼합하여 치킨소스 형태의 식품학적 부형제를 포함하는 지질대사 개선용 조성물을 제조하였다.
The composition formulated in Formulation 5 of Table 1 and each of the ingredients shown in Table 5 as a food acceptable acceptable excipient was mixed to prepare a composition for improving lipid metabolism comprising a food excipient in the form of chicken sauce.

식품학적 부형제를 포함하는 지질대사 개선용 조성물(단위; 중량％)Composition for improving lipid metabolism comprising a food excipient (unit: weight%) 성분ingredient 불고기소스Bulgogi Sauce 성분ingredient 치킨소스Chicken Sauce 조성물(표 1의 배합5)Composition (Combination 5 of Table 1) 0.420.42 조성물(표 1의 배합5)Composition (Combination 5 of Table 1) 0.50.5 마늘,양파,생강Garlic, onion, ginger 12.6712.67 식용유,마늘,양파,생강Cooking oil, garlic, onion, ginger 22.1322.13 전분주정, 감초액Starch alcohol, licorice 9.109.10 감초액, 간장, 소금, 흑설탕, 물엿Licorice solution, soy sauce, salt, brown sugar, syrup 4040 흑설탕,물엿,매실액기스Brown sugar, syrup, plum extract 30.0030.00 고추장, 케첩, 고춧가루, 후추Gochujang, ketchup, red pepper powder, pepper 2020 간장, 소금, 후추, 고춧가루, 참깨Soy sauce, salt, pepper, red pepper powder, sesame seeds 22.6922.69 사과, 배 Apple pear 6.506.50 배, 사과Pear and apple 8.278.27 감초액, 주정Licorice, alcohol 9.119.11 정제수Purified water 16.8516.85 정제수Purified water 1.761.76 합계Sum 100100 합계Sum 100100

*상기 표 5에서 성분 중 2개 이상 기재된 것은 동일한 중량비로 혼합된 혼합물을 의미한다.
* In Table 5, two or more of the components means a mixture mixed in the same weight ratio.

상술한 바와 같이, 본 발명의 바람직한 실시예를 참조하여 설명하였지만 해당 기술 분야의 숙련된 당업자라면 하기의 특허청구범위에 기재된 본 발명의 사상 및 영역으로부터 벗어나지 않는 범위 내에서 본 발명을 다양하게 수정 및 변경시킬 수 있음을 이해할 수 있을 것이다.
Although the preferred embodiments of the present invention have been disclosed for illustrative purposes, those skilled in the art will appreciate that various modifications, additions and substitutions are possible, without departing from the scope and spirit of the invention as disclosed in the accompanying claims. It will be understood that the present invention can be changed.

복분자, 영실자, 사상자 및 옥촉서예의 추출물 또는 분획물의 조성물을 투여 시 상기의 실험예의 결과에서 나타난 바와 같이 지질대사 개선 및 향상 효과가 있다. 따라서 의약품 또는 건강기능식품으로 산업상 이용가능성이 있다.Administration of the extracts or fractions of Bokbunja, Youngsilja, Casualties and Okmok calligraphy has the effect of improving and improving lipid metabolism as shown in the results of the above experimental example. There is therefore industrial applicability as a pharmaceutical or dietary supplement.

Claims (6)

복분자, 영실자, 사상자 및 옥촉서예 추출물을 유효성분으로 함유하는 것을 특징으로 하는 지질대사 개선용 복합 조성물Composite composition for improving lipid metabolism, comprising Bokbunja, Youngsilja, Casualties and Okmok calligraphy extract as an active ingredient 제 1항에 있어서, 전체 중량에 대하여 복분자 추출물은 60∼70중량％, 영실자의 추출물은 10∼15 중량％, 사상자의 추출물은 10∼15 중량％ 및 옥촉서예의 추출물은 10∼15 중량％가 함유되는 것을 특징으로 하는 지질대사 개선용 복합 조성물The method according to claim 1, wherein 60 to 70% by weight of Bokbunja extract, 10 to 15% by weight of extract of Youngsilja, 10 to 15% by weight of extract of casualties, and 10 to 15% by weight of extract of Okmok calligraphy. Complex composition for improving lipid metabolism, characterized in that 복분자, 영실자, 사상자 및 옥촉서예를 분말로 만드는 단계와,
상기의 각각의 분말화된 한약재를 용매로 추출하는 단계와;
상기의 추출물을 여과하고, 여과액을 감압농축하여 동결건조하는 단계를 포함하는 지질대사 개선용 복합 조성물의 제조방법Powdering Bokbunja, Yeongsilja, Casualties and Okmok calligraphy,
Extracting each of the powdered herbal medicines with a solvent;
The method of producing a composite composition for improving lipid metabolism comprising filtering the extract, and lyophilizing the filtrate under reduced pressure. 제3항에 있어서, 용매는 정제수, 메탄올 또는 에탄올인 것을 특징으로 하는 지질대사 개선용 복합 조성물의 제조방법The method of claim 3, wherein the solvent is purified water, methanol, or ethanol. 청구항 제1항의 조성물 또는 청구항 제3항의 방법에 의해 제조한 조성물과 약제학적으로 허용된 부형제를 포함하는 지질대사 개선용 복합 조성물Complex composition for improving lipid metabolism comprising the composition of claim 1 or the composition prepared by the method of claim 3 and a pharmaceutically acceptable excipient 청구항 제1항의 조성물 또는 청구항 제3항의 방법에 의해 제조한 조성물과 식품학적으로 허용된 부형제를 포함하는 지질대사 개선용 복합 조성물Complex composition for improving lipid metabolism comprising the composition of claim 1 or the composition prepared by the method of claim 3 and a food acceptable excipient
KR1020100050557A 2010-05-28 2010-05-28 A composition for improving lipid metabolism which includes extract of rubus coreanus as an active constituent by major KR101173172B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020100050557A KR101173172B1 (en) 2010-05-28 2010-05-28 A composition for improving lipid metabolism which includes extract of rubus coreanus as an active constituent by major

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020100050557A KR101173172B1 (en) 2010-05-28 2010-05-28 A composition for improving lipid metabolism which includes extract of rubus coreanus as an active constituent by major

Publications (2)

Publication Number Publication Date
KR20110130969A true KR20110130969A (en) 2011-12-06
KR101173172B1 KR101173172B1 (en) 2012-08-14

Family

ID=45499571

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020100050557A KR101173172B1 (en) 2010-05-28 2010-05-28 A composition for improving lipid metabolism which includes extract of rubus coreanus as an active constituent by major

Country Status (1)

Country Link
KR (1) KR101173172B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016182161A1 (en) * 2015-05-11 2016-11-17 한국 한의학 연구원 Composition containing rubus coreanus extract or fraction thereof as active ingredient for increasing low-density lipoprotein receptor by inhibiting pcsk9 gene expression, and use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100903970B1 (en) * 2007-09-14 2009-06-25 이상백 The process of make food how to beak down fat in body

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016182161A1 (en) * 2015-05-11 2016-11-17 한국 한의학 연구원 Composition containing rubus coreanus extract or fraction thereof as active ingredient for increasing low-density lipoprotein receptor by inhibiting pcsk9 gene expression, and use thereof

Also Published As

Publication number Publication date
KR101173172B1 (en) 2012-08-14

Similar Documents

Publication Publication Date Title
Matic et al. Investigation of medicinal plants traditionally used as dietary supplements: A review on Moringa oleifera
KR101158856B1 (en) Compositions for the prevention and treatment of obesity, hyperlipidemia, atherosclerosis, fatty liver, diabetes mellitus or metabolic syndrome comprising extracts or fractions of Glycine max leaves as an active ingredient
Morebise A review on Gongronema latifolium, an extremely useful plant with great prospects.
Mann et al. Evaluation of nutritional and antioxidant potential of Indian buckwheat grains
Parra et al. An overview on various aspects of plant Berberis Lycium Royale
Elhassaneen et al. Effect of some plant parts powder on obesity complications of obese rats
KR20100109697A (en) Functional composition with the effects of improving hyperlipidemia and reducing body weight
Zannou et al. Phytochemical and nutritional properties of sumac (Rhus coriaria): a potential ingredient for developing functional foods
KR101160088B1 (en) Herbal extracts composition for the prevention of alcoholic fatty liver, hyperlipidemia and hangover
Mahmoud et al. Germination of Glycine max seeds potentiates its antidiabetic effect in streptozotocin induced diabetic rats
KR101173172B1 (en) A composition for improving lipid metabolism which includes extract of rubus coreanus as an active constituent by major
JP2008214198A (en) Composition characterized by containing morus plants, lotus plants, crataegus plants, and salvia plants
Sarmah et al. Ethnomedicinal plants and their traditional use for treatment of diabetes in Kokrajhar district of Assam
Patel et al. Protective effects of fagonia cretica L. Extract in cafeteria diet induced obesity in wistar rats
KR20090108794A (en) Composition containing complex oriental medicine extract for prevention and treatment of cardiovascular disease
Deepika et al. Pharmacological and Therapeutic Potential of Cucumis callosus: a Novel Nutritional Powerhouse for the Management of Non-communicable Diseases
KR102115398B1 (en) Functional food compound having antioxidant property and allergic dermatitis treatment property and method for manufacturing the same
KR101360233B1 (en) Pharmaceutical composition for preventing or treating lung cancer comprising herbal extracts
Patel et al. A review on flax seed: A legume for longevity
KR101201148B1 (en) Composition comprising extracts of Cedrela sinensis for anti-cancer activity
JP2006257018A (en) Antiobestic agent, medicine and beverage or food
Gandhi et al. Bioactive compounds of amaranth (Genus Amaranthus)
KR100846521B1 (en) Composition comprising an extract of herbal combination(oca-i) or the powder(oca-ii) thereof for preventing and treating diabetes mellitus
KR20070002445A (en) A composition comprising an extract of hgd-sj-201 crude drug complex as an effective ingredient treating or preventing obesity
KR20040008975A (en) Composition having brain function and congnition enhancing activity

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20150804

Year of fee payment: 4

FPAY Annual fee payment

Payment date: 20160727

Year of fee payment: 5

FPAY Annual fee payment

Payment date: 20170908

Year of fee payment: 6

FPAY Annual fee payment

Payment date: 20180823

Year of fee payment: 7